Journal
JOURNAL OF ATTENTION DISORDERS
Volume 15, Issue 4, Pages 286-294Publisher
SAGE PUBLICATIONS INC
DOI: 10.1177/1087054710367880
Keywords
ADHD; adult; clinical trial; methylphenidate
Categories
Funding
- McNeil Pediatrics
- Shire Laboratories, Inc.
- Eli Lilly Company
- Glaxo-Smith Kline
- Janssen Pharmaceutical
- McNeil Pharmaceutical
- Novartis Pharmaceuticals
- Cephalon
- Pfizer
- National Institute of Mental Health
- Ortho-McNeil Janssen Scientific Affairs
- Shire Pharmaceuticals
- Abbott
- Eli Lilly
- Forest
- McNeil
- Shire
- Elminda Ltd
- Bristol Myers Squibb
- Johnson Johnson
- Merck
- New River
- Organon
- Takeda
- Alza
- AstraZeneca
- Janssen Pharmaceuticals Inc.
- Otsuka
- NICHD
- Fundacion Areces
- Medice Pharmaceuticals
- Spanish Child Psychiatry Association
- Celltech
- Esai
- Glaxo
- Gliatech
- Janssen
- NARSAD
- NIDA
- Noven
- Neurosearch
- Pharmacia
- Prechter Foundation
- Stanley Foundation
- UCB Pharma, Inc.
- Wyeth
- ElMinda
- Hilda and Preston Davis Foundation
- National Institutes of Health
- Janssen-Ortho
- MGH Academy/Reed Medical Education
Ask authors/readers for more resources
Objective: The main aim of this study was to examine the efficacy, tolerability, and compliance of an extended-release formulation of methylphenidate (OROS-MPH) in adults with ADHD receiving immediate-release methylphenidate (IR-MPH). Method: Participants were outpatient adults with ADHD who were stable on IR-MPH-administered TID. Participants were randomized (4:1) to equipotent doses of OROS-MPH or to continue IR-MPH and were assessed weekly for 6 weeks with the Adult ADHD Investigator System Symptom Report Scale (AISRS). Results: Randomization of 53 IR-MPH responders to IR- or OROS-MPH had no effect on AISRS score at endpoint (11.2 +/- 6.9 vs. 10.7 +/- 5.1, p = .8). Participants stabilized on IR-MPH and switched to OROS-MPH remained satisfied over 71% of the time. However, the IR-MPH group missed more doses (7.3 +/- 6.8 vs. 3.3 +/- 4.2, p = .02) than the OROS-MPH group. Conclusion: Findings showed that adults with ADHD can be successfully switched from an effective regimen of IR-MPH TID to once-daily OROS-MPH. Results also demonstrated better compliance with OROS-MPH than with IR-MPH treatment. (J. of Att. Dis. 2011; 15(4) 286-294)
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available